Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Arerugi = [Allergy]|June 25, 2010
[Questionnaire for determining relationship between nasal and asthma symptoms]Hiroto Nakada, Kazuyuki Nakagome, Yotaro Takaku, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2019
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancerAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Cancer Chemotherapy and Pharmacology|November 10, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.
Thoracic Cancer|March 14, 2019
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancerTakahiro Uchida, Kyoichi Kaira, Ou Yamaguchi, et al.
Thoracic Cancer|February 28, 2019
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patientsAyako Shiono, Kyoichi Kaira, Atsuto Mouri, et al.
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutationsAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Arerugi = [Allergy]|March 15, 2011
[A case of bronchial asthma caused by occupational exposure to trichophyton]Rie Hoshi, Kazuyuki Nakagome, Hirotoshi Aoki, et al.
Thoracic Cancer|March 20, 2019
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumabOu Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, et al.
Thoracic Cancer|February 19, 2020
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, et al.
Pageof 3